Introduction to Imbruvica (Ibrutinib) 140mg
Imbruvica (Ibrutinib) 140mg is a targeted oral cancer medicine used for the treatment of several blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia. This medicine works by blocking signals that help cancer cells grow and survive.
Imbruvica (Ibrutinib) 140mg is classified under Prescription Medicines, Oncology Medicines, Targeted Cancer Therapies, and Oral Anticancer Drugs. It contains Ibrutinib, which belongs to a group of medicines called Bruton’s Tyrosine Kinase (BTK) inhibitors that specifically target cancer cell growth pathways.
In some markets, Sylhep 140mg is available as a generic brand containing the same active ingredient Ibrutinib, offering a similar therapeutic effect when prescribed by a qualified healthcare professional.
What Is Imbruvica (Ibrutinib)?
Imbruvica is the original brand name for Ibrutinib, an oral targeted therapy widely used to treat certain hematologic (blood-related) cancers.
Ibrutinib belongs to a class of medicines known as Bruton’s Tyrosine Kinase (BTK) inhibitors. These medicines block signals that cancer cells need to grow and spread.
Generic versions such as Sylhep 140mg contain the same active compound and may be used depending on physician recommendation and regional availability.
Drug Class and Mechanism of Action
Ibrutinib is classified as a targeted anticancer medicine and BTK inhibitor with strong antineoplastic activity.
How Ibrutinib Works
It works in several ways:
- Blocks Bruton’s Tyrosine Kinase (BTK) enzyme involved in cancer cell signaling
- Prevents malignant B-cells from growing and multiplying
- Promotes the death of abnormal cancer cells
Through these mechanisms, Ibrutinib helps slow or stop the progression of certain blood cancers.
How Imbruvica Works in the Body
Certain blood cancers grow because abnormal B-cells receive signals that allow them to survive and multiply. Imbruvica blocks these signals.
Key Actions of Ibrutinib
- Blocking BTK signaling in malignant B-cells
- Inhibiting growth and survival of cancer cells
- Reducing accumulation of abnormal lymphocytes
- Supporting immune system balance in cancer treatment
Some generic versions such as Sylhep deliver the same active compound, allowing similar targeted cancer treatment when prescribed appropriately.
Medical Uses of Imbruvica (Ibrutinib) 140mg
Imbruvica 140mg is widely prescribed for several types of blood cancers.
Imbruvica for Chronic Lymphocytic Leukemia (CLL)
Imbruvica is commonly used to treat patients diagnosed with chronic lymphocytic leukemia.
Potential Benefits
- Helps slow disease progression
- Reduces abnormal lymphocyte accumulation
- Improves progression-free survival
Generic alternatives like Sylhep 140mg may also be used under medical supervision when Ibrutinib therapy is recommended.
Imbruvica for Mantle Cell Lymphoma (MCL)
Ibrutinib may be prescribed for patients with mantle cell lymphoma, especially when the disease has relapsed after previous treatments.
Treatment Benefits
- Helps control lymphoma growth
- Improves response in relapsed disease
- Provides an oral targeted therapy option
Imbruvica for Waldenström’s Macroglobulinemia (WM)
Imbruvica is also used in the treatment of Waldenström’s macroglobulinemia, a rare type of blood cancer.
Treatment Benefits
- Reduces abnormal protein levels in blood
- Improves disease control
- Helps manage symptoms of the condition
Who Can Take Sylhep 140mg?
Because Ibrutinib is a potent oncology medicine, treatment should always be supervised by a qualified healthcare provider.
Eligibility Criteria
Patients may be prescribed Imbruvica if they:
- Are diagnosed with CLL, MCL, or Waldenström’s macroglobulinemia
- Require targeted oral cancer therapy
- Can undergo regular blood tests and medical monitoring
Certain generic options such as Sylhep may also be considered depending on availability and physician decision.
Who Should Avoid Imbruvica (Ibrutinib) 140mg
Imbruvica should NOT be used by:
- Patients with hypersensitivity to Ibrutinib
- Individuals with severe bleeding disorders unless monitored by a specialist
- Pregnant women or women planning pregnancy
Imbruvica (Ibrutinib) 140mg Dosage and Administration
Standard Dosage Guidelines
Typical dosage recommendations include:
- Imbruvica 140mg taken as prescribed by a doctor
- Often taken once daily depending on the treatment plan
- Capsules should be swallowed whole with water
- Can be taken with or without food
Dosage Adjustments
Doctors may adjust the dose depending on:
- Liver function
- Blood test results
- Drug interactions with other medications
- Individual treatment response
Side Effects of Imbruvica 140mg
Like all cancer medicines, Imbruvica may cause side effects.
Common Side Effects
- Diarrhea
- Fatigue
- Muscle or joint pain
- Nausea
- Skin rash
Serious Side Effects
- Bleeding complications
- Irregular heartbeat (atrial fibrillation)
- Severe infections
- Low blood cell counts
Patients should report any unusual symptoms to their doctor immediately.
Storage:
Store below 25°C in a cool, dry place, protected from moisture and direct sunlight. Keep the capsules in their original packaging and out of reach of children.
Frequently Asked Questions (FAQs)
1. Is Imbruvica (Ibrutinib) 140mg chemotherapy?
No. Imbruvica is a targeted cancer therapy that blocks specific enzymes responsible for cancer cell growth.
2. How long do patients take Imbruvica?
Treatment duration depends on the patient’s condition and response. Some patients take it for extended periods under medical supervision.
3. Can Imbruvica cure blood cancer?
Imbruvica helps control disease progression and improve survival, but it may not cure the cancer in all cases.
4. Can patients stop Imbruvica suddenly?
No. Stopping treatment without medical advice may allow the cancer to progress. Always consult your doctor.
5. Can Sylhep 140mg be used instead of Imbruvica?
Sylhep 140mg contains Ibrutinib, the same active ingredient found in Imbruvica. Generic versions may provide a similar therapeutic effect when prescribed appropriately. For more information contact on WhatsApp: https://wa.me/8801742433764
6. Do I need a prescription to buy Sylhep (Ibrutinib) 140mg?
Yes. Sylhep 140mg is a prescription-only medicine and must be used under the supervision of a qualified healthcare professional.
Medical Disclaimer
Disclaimer:
The information provided on this page is for educational and informational purposes only and should not be considered medical advice. Imbruvica (Ibrutinib) is a prescription-only medication and must be used strictly under the supervision of a qualified healthcare professional. Always consult your physician before starting, stopping, or changing any medication.
